Press release
Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR during the Study Period (2019-2032) | DelveInsight
Global mRNA-based Vaccines and Therapeutics Market
(Albany, USA) DelveInsight's Global mRNA-based Vaccines and Therapeutics Market Insights report includes a comprehensive understanding of current treatment practices, emerging global mRNA-based vaccines and therapeutics, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Significant developments have been made in mRNA therapy over the past several decades. Many monotherapies and combinations are in trial. Companies are diligently working toward the development of novel treatments. Key players such as BioNTech SE, ModernaTX, CureVac, Sanofi, and others are some of the major players that are going to boost the global mRNA-based vaccines and therapeutics market dynamics in the coming years.
Key Takeaways from the Global mRNA-based Vaccines and Therapeutics Market Report
* According to DelveInsight's analysis, the market size for global mRNA-based vaccines and therapeutics across the 7MM is expected to grow with a significant CAGR by 2032.
* According to the American Cancer Society (2023), in general, about 10-15% of all lung cancers are SCLC, and about 80-85% are NSCLC. In 2023, an estimated 238K adults (117K men and 120K women) in the United States will be diagnosed with lung cancer.
* Leading mRNA-based vaccines and therapeutics companies such as Vertex Pharmaceuticals Incorporated, ReCode Therapeutics, ModernaTX, Inc., Merck Sharp & Dohme LLC, Remix Therapeutics, Audentes Therapeutics, Pfizer, Sirnaomics, Phoenicis Therapeutics, Astellas Pharma US, Inc., Immorna Biotherapeutics, Inc., ICON plc, Sangamo Therapeutics, 2seventy bio, Hillhurst Biopharmaceuticals, Inc., Silence Therapeutics plc, STORM Therapeutics LTD, BioNTech SE, Agomab Therapeutics NV, Alnylam Pharmaceuticals, Janssen Pharmaceutica N.V., AstraZeneca, Ocugen, Merus N.V., Sanofi, Immunomic Therapeutics, and others are developing novel mRNA-based vaccines and therapeutics that can be available in the global mRNA-based vaccines and therapeutics market in the coming years.
* The promising global mRNA-based vaccines and therapeutics in the pipeline include VX-522, RCT1100, mRNA-4157, REM-422, scAAV9.U7.ACCA, PF-06651600, STP705, PTW-002 10, Enzalutamide, JCXH-221, BIVV003, bbT369, HBI-002, SLN124, STC-15, BNT112, AGMB-129, ALN-HSD, JNJ-55308942, AZD8701, BBV152, MCLA-158, SAR441000, ITI-1000, and others.
Discover which therapies are expected to grab the major global mRNA-based vaccines and therapeutics market share @ Global mRNA-based Vaccines and Therapeutics Market Report [https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Global mRNA-based Vaccines and Therapeutics Overview
Messenger RNA (mRNA) is a form of single-stranded ribonucleic acid generated through transcription from a DNA strand. It contains the essential coding information for protein synthesis, which undergoes further transcription and processing to yield functional proteins. The progression of mRNA-based therapeutics encompasses critical stages such as mRNA design, synthesis, mRNA encapsulation, pharmacodynamics, pharmacokinetics, safety assessments in both in vivo and in vitro settings, manufacturing, and clinical trials. The design and synthesis of mRNA stand out as pivotal stages in the development of mRNA-based medications. The therapeutic application of mRNA holds significant promise in addressing a diverse range of incurable diseases. Recent rapid advancements in biotechnology and molecular medicine have empowered the ability to produce nearly any functional protein or peptide within the human body by introducing mRNA as a vaccine or therapeutic agent. This burgeoning field of precision medicine holds considerable potential for preventing and treating numerous challenging or genetic diseases.
Global mRNA-based Vaccines and Therapeutics Epidemiology Segmentation
The global mRNA-based vaccines and therapeutics epidemiology section provides insights into the historical and current global mRNA-based vaccines and therapeutics patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The global mRNA-based vaccines and therapeutics market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Incident Cases of Shortlisted Indications for mRNA Therapy for Oncology
* Total Indication-wise Eligible Cases for mRNA Therapy for Oncology
* Indication-wise Treated Cases of mRNA Therapy for Oncology
Request for sample report @ https://www.delveinsight.com/sample-request/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market [https://www.delveinsight.com/sample-request/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Global mRNA-based Vaccines and Therapeutics Treatment Market
Immunotherapy represents a groundbreaking approach in the field of cancer treatment. The use of mRNA vaccines has become an appealing and potent method for immunotherapy against cancer due to their high effectiveness, specificity, adaptability, ability for rapid and large-scale development, cost-effective manufacturing potential, and safety. Recent advancements in the design and delivery of mRNA vaccines have expedited their development and application in cancer treatment. Extensive research conducted in preclinical and clinical trials has paved the way for the swift progress of mRNA vaccines, particularly evident during the COVID-19 pandemic. These therapeutic cancer vaccines, based on mRNA, are well-received, and the inherent advantage of easy production, comparable to the best traditional vaccine manufacturing methods, positions mRNA vaccines as a promising avenue for cancer immunotherapy.
In 1996, the initial investigation of a cancer vaccine based on mRNA involved testing dendritic cells loaded with RNA in a laboratory setting. Since then, advancements in technology have enhanced the structure, stability, and delivery techniques of mRNA. Currently, numerous clinical trials are actively recruiting cancer patients to explore the efficacy of mRNA-based vaccine therapies. The administration routes for mRNA vaccines encompass intradermal, subcutaneous, intranasal, intranodal, intramuscular, intratumoral, and intravenous delivery.
The majority of cancer vaccines based on mRNA focus on treating existing cancer rather than preventing it, necessitating multiple doses and a significant vaccine strength to elicit a response against tumors when used as the sole form of treatment. While standalone mRNA vaccines may prove effective in treating early-stage cancer or as an additional therapy, their success as a solitary treatment for advanced cancers seems improbable due to the formidable challenges posed by the highly immunosuppressive tumor microenvironment in such cases.
To know more about mRNA-based vaccines and therapeutics, visit @ Global mRNA-based Vaccines and Therapeutics [https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Pipeline mRNA-based Vaccines and Therapeutics and Key Companies
* VX-522: Vertex Pharmaceuticals Incorporated
* RCT1100: ReCode Therapeutics
* mRNA-4157: ModernaTX, Inc./Merck Sharp & Dohme LLC
* REM-422: Remix Therapeutics
* scAAV9.U7.ACCA: Audentes Therapeutics
* PF-06651600: Pfizer
* STP705: Sirnaomics
* PTW-002 10: Phoenicis Therapeutics
* Enzalutamide: Astellas Pharma US, Inc.
* JCXH-221: Immorna Biotherapeutics, Inc./ICON plc
* BIVV003: Sangamo Therapeutics
* bbT369: 2seventy bio
* HBI-002: Hillhurst Biopharmaceuticals, Inc.
* SLN124: Silence Therapeutics plc
* STC-15: STORM Therapeutics LTD
* BNT112: BioNTech SE
* AGMB-129: Agomab Therapeutics NV
* ALN-HSD: Alnylam Pharmaceuticals
* JNJ-55308942: Janssen Pharmaceutica N.V.
* AZD8701: AstraZeneca
* BBV152: Ocugen
* MCLA-158: Merus N.V.
* SAR441000: Sanofi
* ITI-1000: Immunomic Therapeutics
Learn more about the FDA-approved mRNA-based vaccines and therapeutics @ mRNA-based Vaccines and Therapeutics Analysis [https://www.delveinsight.com/sample-request/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Global mRNA-based Vaccines and Therapeutics Market Dynamics
The dynamics of the global mRNA-based vaccines and therapeutics market are expected to change in the coming years. Several mRNA-based vaccine candidates currently in pre-clinical and clinical phases of development are poised to drive the mRNA-based vaccines and therapeutics market in upcoming years, as the field of mRNA-based therapeutics spans from protein replacement therapy and gene editing to vaccination, and continued advancements in mRNA formulation and delivery using different nanomaterials hold the potential to improve the wider use of mRNA for the treatment and prevention of infectious diseases and cancers.
Furthermore, many potential therapies are being investigated for the treatment of various cancers, and it is safe to predict that the treatment space will significantly impact the global mRNA-based vaccines and therapeutics market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the global mRNA-based vaccines and therapeutics market in the 7MM.
However several factors may impede the growth of the global mRNA-based vaccines and therapeutics market. The broader utilization of mRNA-based therapeutics remains constrained by the requirement for enhanced vectors or drug delivery systems, as advanced delivery systems are essential to address issues such as poor stability, cell targeting, and translational efficiency of naked mRNA. Consequently, challenges persist in the delivery of mRNA-based therapeutics, including technical obstacles that need to be overcome for the successful implementation of mRNA-based therapies.
Moreover, global mRNA-based vaccines and therapeutics treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the global mRNA-based vaccines and therapeutics market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the global mRNA-based vaccines and therapeutics market growth.
Global mRNA-based Vaccines and Therapeutics Market Report Metrics
* Study Period: 2019-2032
* Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
* Key mRNA-based Vaccines and Therapeutics Companies: Vertex Pharmaceuticals Incorporated, ReCode Therapeutics, ModernaTX, Inc., Merck Sharp & Dohme LLC, Remix Therapeutics, Audentes Therapeutics, Pfizer, Sirnaomics, Phoenicis Therapeutics, Astellas Pharma US, Inc., Immorna Biotherapeutics, Inc., ICON plc, Sangamo Therapeutics, 2seventy bio, Hillhurst Biopharmaceuticals, Inc., Silence Therapeutics plc, STORM Therapeutics LTD, BioNTech SE, Agomab Therapeutics NV, Alnylam Pharmaceuticals, Janssen Pharmaceutica N.V., AstraZeneca, Ocugen, Merus N.V., Sanofi, Immunomic Therapeutics, and others
* Key Pipeline mRNA-based Vaccines and Therapeutics: VX-522, RCT1100, mRNA-4157, REM-422, scAAV9.U7.ACCA, PF-06651600, STP705, PTW-002 10, Enzalutamide, JCXH-221, BIVV003, bbT369, HBI-002, SLN124, STC-15, BNT112, AGMB-129, ALN-HSD, JNJ-55308942, AZD8701, BBV152, MCLA-158, SAR441000, ITI-1000, and others
Scope of the Global mRNA-based Vaccines and Therapeutics Market Report
* Therapeutic Assessment: Global mRNA-based Vaccines and Therapeutics current marketed and emerging therapies
* Global mRNA-based Vaccines and Therapeutics Market Dynamics: Key Market Forecast Assumptions of Emerging Global mRNA-based Vaccines and Therapeutics Drugs and Market Outlook
* Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Unmet Needs, KOL's views, Analyst's views, Global mRNA-based Vaccines and Therapeutics Market Access and Reimbursement
Discover more about mRNA-based vaccines and therapeutics in development @ mRNA-based Vaccines and Therapeutics Clinical Trials [https://www.delveinsight.com/sample-request/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Global mRNA-based Vaccines and Therapeutics Key Insights
2. Global mRNA-based Vaccines and Therapeutics Report Introduction
3. Global mRNA-based Vaccines and Therapeutics Overview at a Glance
4. Global mRNA-based Vaccines and Therapeutics Executive Summary
5 Global mRNA-based Vaccines and Therapeutics Key Events
6. Epidemiology and Market Forecast Methodology (Disease Background and Overview)
7. Global mRNA-based Vaccines and Therapeutics Treatment and Management
8. Global mRNA-based Vaccines and Therapeutics Guidelines
9. Global mRNA-based Vaccines and Therapeutics Epidemiology and Patient Population
10. Patient Journey
11. Key Endpoints in Global mRNA-based Vaccines and Therapeutics
12. Global mRNA-based Vaccines and Therapeutics Marketed Drugs
13. Global mRNA-based Vaccines and Therapeutics Emerging Drugs
14. 7MM Global mRNA-based Vaccines and Therapeutics Market Analysis
15. Market Access and Reimbursement
16. KOL Views
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-mrnabased-vaccines-and-therapeutics-market-is-expected-to-grow-at-a-decent-cagr-during-the-study-period-20192032-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR during the Study Period (2019-2032) | DelveInsight here
News-ID: 3924402 • Views: …
More Releases from ABNewswire
Viceroy Bali the Luxury Resort in Ubud is Honoured with Prestigious Agoda Gold C …
Recognising Unwavering Commitment to Excellence in Hospitality and Guest Satisfaction
Ubud, Bali - April 22, 2025 - Viceroy Bali, one of Indonesia's most luxurious and celebrated boutique resorts, is proud to announce it has been awarded the prestigious Agoda Gold Circle Award, a distinction that honours outstanding hotel partners who go above and beyond in delivering exceptional service, operational excellence, and guest satisfaction.
Presented annually, the Agoda Gold Circle Award recognises hospitality…
BaldrTherm Launches SolarPowered Smart Sensors Extending Baldr's 12Year Legacy o …
New E0587TH and B0590TH series thermohygrometers harness photovoltaic power.
Image: https://www.abnewswire.com/upload/2025/04/f98c2416097a32b4be547485aeee0859.jpg
BaldrTherm, a leading provider of smart home climate devices, today announced the release of a new lineup of solar-powered indoor thermometer and hygrometer units. These compact devices offer homeowners an easy and eco-friendly way to monitor temperature and humidity in any room. With two display size options and multi-pack choices, the new models provide accurate, real-time readings and user-friendly features to…
CE-LINK Unveils the 5-in-1 Type-C Hub with Qi2 Wireless Charging as the Ultimate …
Image: https://www.abnewswire.com/upload/2025/04/2ad3a8179a096196323ae4775023fc8f.jpg
As our digital lives become more device-dependent, managing cluttered desks and tangled cables can be a hassle. CE-LINK addresses these challenges with the launch of the 5-in-1 Type-C Hub with Qi2 Wireless Charging, a groundbreaking product designed to streamline your tech experience.
One Step Ahead of Its Competition
Unlike traditional hubs that focus solely on connectivity, CE-LINK integrates wireless charging technology into the hub, offering a one-stop solution for all your…
Shenzhen Honest Intelligent Equipments Co., Ltd. Sets New Standard in Automotive …
Image: https://www.abnewswire.com/upload/2025/04/47f60f6da6a0ce743b99e5d42e6cb196.jpg
Founded in 2007, Shenzhen HONEST Intelligent Equipments Co., Ltd. has become a major player in the field of automotive motor automation equipment, providing cutting-edge, tailored intelligent solutions for auto parts manufacturers and cars. The company, now acknowledged as a national high-tech enterprise and a specialized new enterprise with 19 years of industry experience, serves a wide range of customers, including worldwide leaders such as BYD, Toyota, Valeo, Nexteer Automotive,…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
